Red yeast rice
Red yeast rice (RYR), a product made from cultivating rice with the mold Monascus purpureus, has been used in China for centuries to treat circulatory and digestive disorders – and apparently without a bit of controversy. RYR has been in use in the U.S. for a much shorter period of time (as a non-prescription cholesterol-lowering supplement), and has generated lots of controversy.
The Controversy and Confusion Over RYR
The controversy began in 1999, shortly after clinical trials first showed that RYR could indeed significantly lower cholesterol levels. At that time it came to the attention of the FDA that RYR’s effectiveness is related to the fact that it contains a naturally-occurring form of the statin drug lovastatin (marketed as Mevacor). So the FDA ruled that RYR was a regulable drug, and thus ordered it removed it from the shelves.
This FDA decision was initially overruled by the District Court of Utah in 1999, but in 2000 the 10th U.S. Circuit Court of Appeals agreed with the FDA that RYR could be regulated. So RYR could still be sold legally in the U.S., but only if steps were taken in its manufacturing process to remove the lovastatin (presumably eliminating its effectiveness).
Then, in 2007, the FDA found that at least some RYR in the U.S. still contained lovastatin, and (after issuing a formal FDA Consumer Safety Alert) took further steps to purge the “tainted” products from the shelves.
Currently, as far as the FDA is concerned, the RYR that you can buy in the U.S. contains no lovastatin. But otherwise, RYR is still considered a dietary supplement, so its formulation and content is still not regulated — and it is very difficult if not impossible to find out what it does contain. (This is the case with any unregulated dietary supplement.)
But Does It Work?
In the face of all this confusion, two clinical trials have appeared in the last few years that show that at least some RYR legally available in the U.S. is still effective in reducing cholesterol levels.
In 2009, a study from Pennsylvania showed that in 60 patients who had to stop taking statin drugs because of muscle pain, taking RYR and initiating lifestyle changes for 24 weeks significantly reduced total and LDL cholesterol levels, compared to taking a placebo and making the same lifestyle changes.
And in 2010, investigators from the University of Pennsylvania reported that in patients who had to stop taking statins due to muscle pain, RYR was just as effective as 20 mg per day of the statin drug pravastatin (Pravachol) in reducing cholesterol levels. (Both RYR and pravachol produced only a very low incidence of recurrent muscle pain.)
In the 2009 study, the investigators performed a formal chemical analysis on the RYR product they used in their study (from Sylvan Bioproducts in Kittanning, Pennsylvania). They found that the RYR contained monacolin K (the naturally-occurring form of lovastatin), as well as eight other monacolins (statins or statin-like substances).
The result of this chemical analysis suggests two things. First, that RYR available in the U.S. apparently still contains at least some lovastatin, and second, even if all the lovastatin were completely removed (which appears to be much harder to do than the FDA thinks) other, similar chemicals in RYR may be effective in reducing cholesterol.